Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Anti-inflammatory Dupixent's sales are up 15%, and a midstage trial of treatment for muscle loss caused by obesity drugs is fully ... patients around the world, Regeneron Chief Executive Leonard ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

“The world needed this to exist,” Myerson says. The Regeneron Genetics Center has pledged to sequence the exomes—the protein-coding parts of genomes—of the project’s first 10 million ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara ... delivering an average surprise of 4.10%. Amgen is scheduled to release fourth-quarter results on ...